Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > AMAG Pharmaceuticals, Inc. Reports on Progress Toward Commercialization and Discusses Key Activities for 2008 at 26th Annual JPMorgan Healthcare Conf

Abstract:
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and CEO of AMAG Pharmaceuticals, Inc., will provide a company update at the 26th Annual JPMorgan Healthcare Conference at 11:00 a.m. PT on Tuesday, January 8, 2008, at the Westin St. Francis Hotel in San Francisco, CA.

AMAG Pharmaceuticals, Inc. Reports on Progress Toward Commercialization and Discusses Key Activities for 2008 at 26th Annual JPMorgan Healthcare Conf

Cambridge, MA | Posted on January 8th, 2008

Brian J.G. Pereira, MD, President and CEO, will present a market overview and discuss commercialization opportunities for ferumoxytol, the Company's key product candidate being developed as an intravenous iron replacement therapy for the treatment of iron deficiency anemia in patients with chronic kidney disease (CKD). Dr. Pereira will also discuss additional opportunities for ferumoxytol in oncology and women's health.

Highlights of the presentation will include:

* The current and future market opportunity, commercialization strategy and growth opportunities for ferumoxytol in CKD and other indications.
* The role of ferumoxytol in anemia management including its safety, efficacy and convenience profile and the increased focus on optimizing iron therapy for anemia management.
* Details of two new planned clinical trials for ferumoxytol in chemotherapy-induced anemia (CIA) and abnormal uterine bleeding (AUB) scheduled to begin in mid 2008.
* Preparation for the anticipated U.S. ferumoxytol launch in the first half of 2009.
* Analyst day event planned for the second quarter of 2008.

Webcast information

A live webcast of the presentation will be accessible through the Investors section of the Company's web site at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. web site until February 8, 2008.

Sources:

1. Arias E, Anderson RN, Kung HC, Murphy SL, Kockanek KD. Deaths: Final data for 2001. National Vital Statistics Reports 2003;52(3):1-115.

2. End-Stage Renal Disease Incidence and Prevalence: United States Renal Data Systems 2007 Annual Data Report. 2007, pp 81-98.

####

About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia, as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

Ferumoxytol, the Company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in patients with CKD. The Company has released data on all four of its planned Phase III clinical trials of ferumoxytol as an intravenous iron replacement therapeutic in patients with CKD. The Company filed a New Drug Application for ferumoxytol with the U.S. FDA in December 2007.

Combidex®, the Company’s other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with MRI to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, AMAG Pharmaceuticals, Inc. received an approvable letter from the U.S. Food and Drug Administration with respect to Combidex subject to certain conditions.

About Chronic Kidney Disease

Kidney disease is the ninth leading cause of death in the United States1. CKD is associated with premature mortality, decreased quality of life, and increased health care expenditures. CKD can progress to end-stage renal disease and require dialysis or kidney transplantation. The U.S. Renal Data System estimated that in 2005 the dialysis population was over 340,000 patients2.

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained in this press release that do not describe historical facts, including but not limited to, statements regarding our potential ferumoxytol opportunities in oncology and women’s health, new clinical trials for ferumoxytol in CIA and AUB scheduled to begin in mid 2008, the anticipated ferumoxytol launch in the first half of 2009 and a potential analyst day event in the second quarter of 2008, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include the following: (1) the possibility that we may not be able to obtain the necessary regulatory approvals in order to market and sell ferumoxytol, or we may not obtain such approvals in a timely manner; (2) the fact that we have limited sales and marketing expertise; (3) uncertainties relating to our patents and proprietary rights; and (4) other risks identified in our Securities and Exchange Commission filings. We caution readers not to place undue reliance on any forward-looking statements which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

For more information, please click here

Contacts:
AMAG Pharmaceuticals, Inc.
Carol Miceli, 617-498-3361

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

GLOBALFOUNDRIES to Expand Presence in China with 300mm Fab in Chongqing: Company plans new manufacturing facility and additional design capabilities to serve customers in China May 31st, 2016

Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology May 31st, 2016

UK NANOSAFETY GROUP publishes 2nd Edition of guidance to support safe working with nanomaterials May 30th, 2016

Fast, stretchy circuits could yield new wave of wearable electronics May 30th, 2016

Investments/IPO's/Splits

Nanometrics Announces Upcoming Investor Events May 10th, 2016

ORIG3N Added to Companies Presenting at Harris & Harris Group's Annual Meeting, Tuesday June 7, 2016, the New York Genome Center April 27th, 2016

Aspen Aerogels to Present at the 28th Annual ROTH Conference March 14th, 2016

Harris & Harris Group Announces Formation of Co-Investment Fund for Accredited Investors March 9th, 2016

Nanomedicine

Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology May 31st, 2016

Automating DNA origami opens door to many new uses: Like 3-D printing did for larger objects, method makes it easy to build nanoparticles out of DNA May 30th, 2016

Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016

Scientists illuminate a hidden regulator in gene transcription: New super-resolution technique visualizes important role of short-lived enzyme clusters May 27th, 2016

Announcements

GLOBALFOUNDRIES to Expand Presence in China with 300mm Fab in Chongqing: Company plans new manufacturing facility and additional design capabilities to serve customers in China May 31st, 2016

Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology May 31st, 2016

UK NANOSAFETY GROUP publishes 2nd Edition of guidance to support safe working with nanomaterials May 30th, 2016

Fast, stretchy circuits could yield new wave of wearable electronics May 30th, 2016

Events/Classes

Novel gene therapy shows potential for lung repair in asthma May 18th, 2016

Arrowhead Pharmaceuticals' Preclinical Candidate ARC-LPA Achieves 98% Knockdown and Long Duration of Effect after Subcutaneous Administration May 10th, 2016

Nanometrics Announces Upcoming Investor Events May 10th, 2016

Oxford Instruments Asylum Research and McGill University Announce the McGill AFM Summer School and Workshop, May 12-13, 2016 May 4th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic